Affinity Asset Advisors
ODTX icon

Affinity Asset Advisors’s Odyssey Therapeutics ODTX Stock Holding History

Affinity Asset Advisors’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28M Buy
1,260,000
+493,654
+64% +$10.5M 1.14% 25
2026
Q2 		$14.3M Buy
+766,346
New +$13.4M 0.65% 44

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lightspeed Management Company
Lightspeed Management Company Menlo Park, California $2.03B AUM 10.68% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Affinity Asset Advisors's ODTX Position: Q3 2026 in Review

Affinity Asset Advisors increased its Odyssey Therapeutics (ODTX) stake by 64% in Q3 2026, buying an estimated $10.5M and bringing the position to 1,260,000 shares worth $28M. The position accounts for 1.14% of the portfolio, ranked #25.

Affinity Asset Advisors first reported a position in ODTX in Q2 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

  • Affinity Asset Advisors held 1,260,000 shares of Odyssey Therapeutics worth $28M as of Q3 2026.
  • Affinity Asset Advisors bought 493,654 Odyssey Therapeutics shares in Q3 2026, an estimated $10.5M.
  • Odyssey Therapeutics made up 1.14% of Affinity Asset Advisors's portfolio in Q3 2026, its #25 holding.
  • Affinity Asset Advisors first reported a position in Odyssey Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.